Novartis acquires DTx Pharma

Alnylam Pharmaceuticals declares positive Phase 1 results for ALN-APP in Alzheimer's disease study

Pulmatrix submits PUR3100 IND application to US FDA

FDA grants traditional approval for Leqembi as Alzheimer's disease treatment

Bayer Starts Phase III Studies with Investigational Contrast Agent

Enveric Biosciences Develops Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Acadia Pharmaceuticals Adds Phase 3 Development Candidate ACP-101 for Prader-Willi Syndrome

FDA advisory committee confirms clinical benefit of Leqembi for early Alzheimer's disease

Padagis launches Tazarotene Gel and Methylphenidate Transdermal System

Atara Biotherapeutics announces presentation of updated data for tab-cel clinical effectiveness at ASCO 2023

Avrobio Touts Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Bloom Science names new board chair

Angelini Pharma, JCR Pharmaceuticals Forge Global Collaboration for the Development, Commercialization of Novel Epilepsy Therapies

FSD Pharma completes dosing of first cohort in MS trial

Acorda Therapeutics, Chance Pharmaceuticals Team to Commercialize Inbrija in China